New York’s court calendar is getting a deadline that AQST investors will want to mark, and it’s not some far-off “someday.” A class action lawsuit has already been filed, and Misryoum newsroom reported that the lead plaintiff deadline is May 4, 2026.
The notice is specifically aimed at purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) during the “Class Period” running from June 16, 2025 through January 8, 2026, inclusive. If you fall in that window, the filing reminder says you may be able to seek compensation through a contingency-fee arrangement, without paying out of pocket fees or costs—assuming the case moves forward the way these suits are typically structured.
What’s driving the legal theory is the company’s New Drug Application for Anaphylm. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose the true state of Aquestive’s NDA for Anaphylm. Misryoum editorial desk noted that the complaint also alleges Aquestive concealed or minimized the significance of the human factors involved in the use and deployment of its sublingual film—things like packaging, use, administration, and labeling.
Once the “true details” entered the market, the lawsuit claims investors suffered damages. That part matters because it’s the bridge between what the complaint says was hidden or played down, and the harm it argues shareholders experienced later. And it’s also the point where these cases tend to get very document-heavy, the sort of disputes where a single phrase in an application review or label change can suddenly feel like the whole story.
For investors considering involvement, Misryoum analysis indicates there are two main actions being emphasized right now: joining the class action and, if someone wants the lead role, moving the Court no later than May 4, 2026. The notice states that a lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. A bit of a practical detail shows up alongside the legal framing—like, the idea that you can still remain an absent class member and do nothing at this point.
The document also repeats a familiar warning and option set found in these notices: “No Class Has Been Certified.” Until a class is certified, you are not represented by counsel unless you retain one. It also says an investor’s ability to share in any potential future recovery isn’t dependent upon serving as lead plaintiff. Misryoum newsroom also flagged the note that you may select counsel of your choice.
One small real-world moment is easy to imagine here: someone at a kitchen table, phone buzzing with reminders, the smell of coffee still hanging around while they scan the dates and deadline language. Not glamorous, but these notices land in real lives. And while the notice pushes a particular firm and contact details, the core business question for AQST holders is whether they want to be part of the class—now—before the lead-plaintiff window closes.